Open Orphan name change to hVIVO effective 26th October 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that further to its announcement on 8 September 2022, the Company’s change of name to hVIVO plc (LON:HVO) has now been completed and is expected to take effect on AIM and Euronext Growth from 8.00 am tomorrow.

The Company’s ticker will be HVO and the website address (including the investor relations content and the information required by AIM Rule 26 and Euronext Growth Rule 3.4) will be available at www.hvivo.com.

The Company’s ISIN (GB00B9275X97) and SEDOL (B9275X9) will remain the same.

Shareholders will be unaffected by the change of name and existing share certificates should be retained and will remain valid. Any new share certificates issued after the name change takes effect will bear the name hVIVO plc.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

hVIVO plc

hVIVO achieves record revenue, up 30% YoY to £50.6 million

hVIVO plc (LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced a trading update for the period ended 31

hVIVO plc

Hvivo’s consultancy division Venn lands €3.2m pharma contract

Venn Life Sciences, the consultancy services division of Hvivo, has secured a two-year contract with a pharmaceutical client worth €3.2m. A consultancy team based in the Netherlands will provide drug test consultancy and programming services to this global

hVIVO plc

hVIVO’s Venn Life Sciences signs contract worth €3.2m

hVIVO plc (LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its consultancy services division, Venn Life Sciences, has signed

hVIVO plc

Venn Life Sciences: Pharmacokinetics course

Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time course, of an administered drug within the body.

hVIVO plc

HVIVO secures €5.9m contract for cold virus vaccine trials

hVIVO has secured a £5.2m (€5.9m) contract with an unnamed global biotechnology company based in the Asia Pacific region to test its respiratory synctial virus vaccine (RSV) candidate. The US saw an alarming surge in the number of children

hVIVO plc

Hvivo inks €5.9m contract with Asia-Pacific biotech

Hvivo, a Dublin and London-listed pharmaceutical company formerly known as Open Orphan, has signed a contract worth £5.2 million (€5.9m) to test an Asia-Pacific-based biotechnology company’s respiratory virus vaccine using the Irish company’s human challenge trial model. The

hVIVO plc

hVIVO signs £5.2m contract with a global biotechnology company

hVIVO plc (LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £5.2m contract with

hVIVO plc

FluCamp 2022

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

hVIVO plc

Colds and flu causing more work absence than Covid

The UK is now losing more working days to flu, cough and cold-related infections than Covid-19, new data show. Scientists have suggested that the sudden increase in “super colds” forcing people out of work is linked to the pandemic lockdowns

hVIVO plc

hVIVO Phase I results for Imutex’s mosquito vaccine candidate published

hVIVO plc (LON:HVO), (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced publication of previously reported positive data from a first-in-human

hVIVO plc

HVIVO helps big pharma amidst ‘tripledemic’

The Americans have coined a term for it – the cocktail of flu, Covid and RSV. They call it the ‘tripledemic’. Barclays Capital, tracking the experience of the US, believes this toxic combination could be a problem as

hVIVO plc

The Annual Flu Jab: How do we know it’s effective?

Each year studies are performed to determine how well Flu Jabs are protecting members of the public from influenza. While each year varies in the strain of influenza circulating and the effectiveness of the vaccine at fighting the

hVIVO plc

Alexander Mann speaking at World Antiviral Congress 2022

Alexander Mann | Senior Director, Clinical Sciences Alex Mann has a specific interest in the use of human challenge models to answer key questions around host responses to infection as well as efficacy of treatments and vaccines. Over the last

hVIVO plc

Human Challenge Studies: Their conduct and safety aspect

If there would be a survey of 100 clinical research professionals either from CRO or from Pharma/Biotech industry to explain what a human challenge study is, the most common answer most probably would be – “I have never heard of

hVIVO plc

FluCamp interview Research Nurse Claudia Machado

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

No more posts to show